Acute Portal Vein Thrombosis Management

Initial Management Strategy

The American Society of Hematology recommends anticoagulation should be initiated immediately in all patients with acute portal vein thrombosis to prevent thrombus extension, mesenteric infarction, and achieve recanalization 1, 2
Start therapeutic anticoagulation as soon as acute PVT is diagnosed, regardless of whether the patient has cirrhosis or not, as recommended by the American College of Chest Physicians 3, 4
Early anticoagulation prevents thrombus extension in virtually all patients and prevents the catastrophic complication of mesenteric venous infarction, according to the European Association for the Study of the Liver 4
Delayed initiation of anticoagulation is associated with failure to achieve recanalization, as stated by the European Association for the Study of the Liver 4

Before starting anticoagulation, implement adequate prophylaxis for gastrointestinal bleeding, particularly variceal bleeding screening and management, as recommended by the American Association for the Study of Liver Diseases 5, 1
Evaluate for presence of esophageal varices via endoscopy, and ensure varices are adequately treated with beta-blockers or band ligation before anticoagulation, according to the American Association for the Study of Liver Diseases 5, 1
Assess platelet count and bleeding risk factors, as recommended by the International Society on Thrombosis and Haemostasis 1, 2

For patients without cirrhosis, the American College of Chest Physicians recommends using LMWH or fondaparinux as initial therapy 3, 4
For patients with cirrhosis, the choice of anticoagulant depends on Child-Pugh classification, as stated by the International Society on Thrombosis and Haemostasis 1, 2, 6
The International Society on Thrombosis and Haemostasis endorses DOACs for Child-Pugh A and B cirrhosis, representing the most current evidence 1, 2

Treat for at least 6 months in all patients with acute PVT, as recommended by the European Association for the Study of the Liver 5, 1
Continue anticoagulation beyond 6 months in patients with liver transplant candidates, superior mesenteric vein involvement with history of intestinal ischemia, underlying permanent prothrombotic conditions, or incomplete recanalization in transplant candidates, according to the European Association for the Study of the Liver 5, 1

Assess thrombus extension with CT or MRI, and monitor for recanalization at regular intervals during the first 6 months, as recommended by the European Association for the Study of the Liver 5, 4
Poor prognostic indicators for recanalization include delayed anticoagulation initiation, as stated by the European Association for the Study of the Liver 4

Do not withhold anticoagulation for moderate thrombocytopenia, as recommended by the International Society on Thrombosis and Haemostasis 2, 6
Full-dose anticoagulation is appropriate when platelets >50 × 10⁹/L, according to the International Society on Thrombosis and Haemostasis 2
Consider platelet support in the initial 30 days if needed, as stated by the International Society on Thrombosis and Haemostasis 6

The risk of NOT anticoagulating (intestinal infarction, death) exceeds the bleeding risk, as stated by the European Association for the Study of the Liver 4
Active bleeding is the primary contraindication, according to the International Society on Thrombosis and Haemostasis 1